Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.
about
In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animalsAdipose stromal cells amplify angiogenic signaling via the VEGF/mTOR/Akt pathway in a murine hindlimb ischemia model: a 3D multimodality imaging studyAdvances in Molecular Imaging Strategies for In Vivo Tracking of Immune CellsIncreased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review.Recent advances in imaging the lungs of intact small animals.NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imagingCytokine-induced NK-like T cells: from bench to bedside.Intravenous transplantation of allogeneic bone marrow mesenchymal stem cells and its directional migration to the necrotic femoral headNK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities.Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cellsCancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse modelsRaf kinase inhibitor protein suppresses nuclear factor-κB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression.Bioluminescence imaging in vivo - application to cancer research.Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression.Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells.Assessing siRNA pharmacodynamics in a luciferase-expressing mouse.Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.Optical imaging in vivo with a focus on paediatric disease: technical progress, current preclinical and clinical applications and future perspectivesCD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapyCD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHDMolecular imaging of cell-based cancer immunotherapy.Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantationShifting foci of hematopoiesis during reconstitution from single stem cellsIn vivo cell tracking with bioluminescence imaging.Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.The imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility.Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.Aptamer technology for tracking cells' status & function.Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cellsDonor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsetsLow doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism
P2860
Q27006069-B2D27A54-26C5-4F60-9FF7-EAEA6779D484Q27317398-D28562C0-24D6-4615-8AB5-602E48E76879Q28076866-EF15B3C4-3F60-4768-BC6D-097824B84EC3Q30238975-3F7D723C-0570-4998-84CB-752BF77DFCC8Q33196903-337850B7-B837-42B0-89AD-010D744DBB7AQ33706001-B30AF6CA-190D-4790-A8DD-CFA896EF288AQ33762499-601CBF9C-D0E7-4CED-A4E1-1A32365149CCQ33793184-A75066C1-A244-4EB7-91CB-FF430B062B5AQ33887452-93A3E73C-1F5A-4C86-8FE1-3E59414CC688Q33893091-582339D5-6F11-4CCA-B638-93597124931CQ34049387-292FC95B-90DB-4955-91A9-E9863BF7868BQ34065630-2E321E87-5F16-4E95-BF92-C2AA0CABF0EFQ34164712-481562B9-2F72-4D80-A790-C9A194A7315EQ34241451-882637F8-9439-45FF-A373-250EF9B2005FQ34259005-7A3AD174-CD75-4A35-BC1F-884E655BF5E2Q34266251-99FAE77C-4041-487A-9BF3-157259F0054AQ34340643-FAD2BC78-D476-4021-BA06-33F967281566Q34382415-4BC57D9C-544D-4EDF-8D5A-22282E365496Q34457509-B6059E37-2AE9-4CF9-B3E4-5541B5A4833EQ34540657-A13856E5-C061-4BDA-B6F8-7419AE45B123Q34544842-36C39455-69C6-4535-A8DD-72722F17056FQ34551230-44E7D9B5-3248-4A0F-87D5-E11C68E72865Q34552894-93272988-E27B-4760-BBD3-D3EB085CB85AQ34707286-79AE0A7B-3666-4DE8-858A-9A15E19F1441Q34717870-9995223C-9196-4C60-8047-EAC0CECF3546Q34757261-C55B4063-7923-4326-B09E-50DCE8CBBB62Q35085385-EA8FFEC5-FBA6-497B-81E5-0638B07E94C5Q35122188-20CC4576-56F1-43D9-84AC-5A01886A6C31Q35162679-B8F1B357-7BEF-4F22-99F1-64615CB10F29Q35483880-CA43014B-AC55-430D-9684-1C74A1FA10FCQ35553621-19DC0A84-0E6B-4BC5-82E9-AEBDC7A8BC3BQ35600095-84A235A7-1F8C-48F7-A034-F7C2D7D9228CQ35642522-032D5A0F-5CE2-4B82-A5A4-38FC178ABBDCQ35662003-285FA3E8-089F-4723-97D2-ED62ABE2860AQ35673895-C5C0D6A0-1EDF-4065-AE1B-19B0276F78C7Q35743830-ADDD5AC0-0CE9-43C0-A5DC-8D6C61DBA65BQ35743874-F922BDB5-2AEE-4CC9-9964-B74B686CEB36Q35763504-D3EBCBEA-0546-4048-BC9C-A40E65973FD8Q35847952-BE45BE86-7C56-46A4-89B3-D3F149FDDB79Q35866143-376A1696-631B-4A36-867F-4D28290D7CFF
P2860
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Revealing lymphoma growth and ...... vivo bioluminescence imaging.
@en
Revealing lymphoma growth and ...... vivo bioluminescence imaging.
@nl
type
label
Revealing lymphoma growth and ...... vivo bioluminescence imaging.
@en
Revealing lymphoma growth and ...... vivo bioluminescence imaging.
@nl
prefLabel
Revealing lymphoma growth and ...... vivo bioluminescence imaging.
@en
Revealing lymphoma growth and ...... vivo bioluminescence imaging.
@nl
P2093
P50
P1433
P1476
Revealing lymphoma growth and ...... vivo bioluminescence imaging.
@en
P2093
Michael R Verneris
Robert S Negrin
P304
P356
10.1182/BLOOD-2002-06-1751
P407
P577
2002-09-26T00:00:00Z